MNKD
Price:
$6.84
Market Cap:
$1.89B
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect ...[Read more]
Industry
Biotechnology
IPO Date
2004-07-28
Stock Exchange
NASDAQ
Ticker
MNKD
According to MannKind Corporation’s latest financial reports and current stock price. The company's current PE Ratio is 85.50. This represents a change of 405.49% compared to the average of 16.91 of the last 4 quarters.
The mean historical PE Ratio of MannKind Corporation over the last ten years is -13.50. The current 85.50 PE Ratio has changed -63453.67% with respect to the historical average. Over the past ten years (40 quarters), MNKD's PE Ratio was at its highest in in the December 2023 quarter at 175.15. The PE Ratio was at its lowest in in the June 2024 quarter at -172.52.
Average
-13.50
Median
-7.18
Minimum
-81.41
Maximum
2.33
Discovering the peaks and valleys of MannKind Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 574.03%
Maximum Annual PE Ratio = 2.33
Minimum Annual Increase = -246.03%
Minimum Annual PE Ratio = -81.41
Year | PE Ratio | Change |
---|---|---|
2023 | -81.41 | 574.03% |
2022 | -12.08 | 1.79% |
2021 | -11.87 | -2.51% |
2020 | -12.17 | 188.14% |
2019 | -4.22 | 140.47% |
2018 | -1.76 | -14.44% |
2017 | -2.05 | -188.04% |
2016 | 2.33 | -246.03% |
2015 | -1.60 | -84.23% |
2014 | -10.13 | 24.47% |
The current PE Ratio of MannKind Corporation (MNKD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-35.12
5-year avg
-24.35
10-year avg
-13.50
MannKind Corporation’s PE Ratio is greater than BioMarin Pharmaceutical Inc. (37.97), greater than Vaxcyte, Inc. (-21.57), greater than Liquidia Corporation (-6.98), greater than Legend Biotech Corporation (-21.42), greater than Bio-Techne Corporation (74.98), greater than United Therapeutics Corporation (14.97), greater than Larimar Therapeutics, Inc. (-6.07), greater than Day One Biopharmaceuticals, Inc. (-15.73), greater than Kiniksa Pharmaceuticals, Ltd. (-168.32), greater than Verastem, Inc. (-1.72), less than ImmunoGen, Inc. (322.18), greater than Immutep Limited (-57.96), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than Elevation Oncology, Inc. (-0.85), less than Acer Therapeutics Inc. (0), greater than NRx Pharmaceuticals, Inc. (-0.96), greater than Pasithea Therapeutics Corp. (-0.68), greater than SAB Biotherapeutics, Inc. (-0.00), greater than MiNK Therapeutics, Inc. (-0.64), greater than Affimed N.V. (-0.01), greater than Adaptimmune Therapeutics plc (-0.54), greater than Sangamo Therapeutics, Inc. (-3.77), greater than null (-2.90),
Company | PE Ratio | Market cap |
---|---|---|
37.97 | $12.25B | |
-21.57 | $11.04B | |
-6.98 | $901.38M | |
-21.42 | $7.51B | |
74.98 | $11.33B | |
14.97 | $16.65B | |
-6.07 | $393.05M | |
-15.73 | $1.38B | |
-168.32 | $1.54B | |
-1.72 | $178.03M | |
322.18 | $8.73B | |
-57.96 | $280.00M | |
-91.78 | $794.69M | |
-0.85 | $35.67M | |
0 | $0 | |
-0.96 | $14.63M | |
-0.68 | $3.93M | |
-0.00 | $28.89M | |
-0.64 | $26.89M | |
-0.01 | $39.90M | |
-0.54 | $176.64M | |
-3.77 | $392.26M | |
-2.90 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is MannKind Corporation's PE Ratio?
How is the PE Ratio calculated for MannKind Corporation (MNKD)?
What is the highest PE Ratio for MannKind Corporation (MNKD)?
What is the 3-year average PE Ratio for MannKind Corporation (MNKD)?
What is the 5-year average PE Ratio for MannKind Corporation (MNKD)?
How does the current PE Ratio for MannKind Corporation (MNKD) compare to its historical average?